Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Co...
February 20 2020 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
it will report fourth quarter and full year 2019 financial results
on Wednesday, February 26, 2020 after the market close.
Management will host a conference call at 9:00 AM ET on
Thursday, February 27, 2020, to review financial results and
provide an update on corporate developments. Following
management’s formal remarks, there will be a question and answer
session.
Participants are asked to pre-register for the call through the
following link:
http://dpregister.com/10139032. Please note
that registered participants will receive their dial in number upon
registration and will dial directly into the call without delay.
Those without internet access or unable to pre-register may dial in
by calling: 1-866-777-2509 (domestic) or 1-412-317-5413
(international). All callers should dial in approximately 10
minutes prior to the scheduled start time and ask to be joined into
the Alimera Sciences call. The conference call will also be
available through a live webcast, which can be accessed through the
following link:
https://services.choruscall.com/links/alimera200220.html, which is
also available through the company’s website at
https://investor.alimerasciences.com/events-and-presentations.
A webcast replay of the call will be available approximately one
hour after the end of the call through May 27, 2020. The
replay can be accessed through the above links or by calling
1-877-344-7529 (domestic) or 1-412-317-0088 (international) and
using access code 10139032. The telephonic replay will be available
until March 12, 2020.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals for the management of
retinal diseases. Alimera is presently focused on diseases
affecting the back of the eye, or retina, because these diseases
are not well treated with current therapies and will affect
millions of people in our aging populations. For more information,
please visit www.alimerasciences.com.
For press inquiries: Jules Abraham for Alimera
Sciences 917-885-7378 julesa@coreir.com |
For investor inquiries: Scott Gordon for Alimera
Sciences scottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024